Ana Callejo

Ana Callejo

Auto-generated profile, based on publicly available information

Ana Callejo

Spanish Lung Cancer Group, (GECP), Barcelona, Spain; Vall d'Hebron University Hospital, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JRJordi Remon
Jordi Remon
BBBenjamin Besse
Benjamin Besse
SASantiago Ponce Aix
Santiago Ponce Aix
ACAna Callejo
Ana Callejo
KAKamal Al-Rabi
Kamal Al-Rabi
RDRafal Dziadziuszko
Rafal Dziadziuszko
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Osimertinib has been established as a standard of care for patients with common sensitizing EGFR-mutant advanced non–small-cell lung cancer (NSCLC) although the sequential approach (first-generation inhibitor gefitinib followed by osimertinib) has not been formally compared. The phase II APPLE trial (ClinicalTrials.gov identifier: NCT02856893 ) enrolled 156 treatment-naïve patients, and two treatment strategies were evaluated: osimertinib up front or the sequential treatment approach with gefitinib up front followed by osimertinib at the time of progression, either molecular progression (detection of plasma T790M resistance mutation) regardless of the radiologic status or just at the time of radiologic progression. Patients' characteristics were well balanced, except for the higher proportion of baseline brain metastases in the sequential approach (29% v 19%). Per protocol, 73% of patients switched to osimertinib in the sequential arm. Up-front treatment with osimertinib was associated with a lower risk of brain progression versus the sequential approach (hazard ratio [HR], 0.54 [90% CI, 0.34 to 0.86]), but a comparable overall survival was observed between both strategies (HR, 1.01 [90% CI, 0.61 to 1.68]), with the 18-month survival probability of 84% and 82.3%, respectively. The APPLE trial suggests that a sequential treatment approach is associated with more frequent progression in the brain but a similar survival in advanced EGFR-mutant NSCLC.

1 August 2001 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PDF file
Alicia ArmentiaAlicia Armentia
Alicia Armentia
CBC. Bañuelos
C. Bañuelos
MAM. L. Arranz
M. L. Arranz
VVV. Del Villar
V. Del Villar
JMJ.‐M. Martín‐Santos
J.‐M. Martín‐Santos
CPC. Paredes
C. Paredes

26 February 2022 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
PFPaula Jimenez Fonseca
Paula Jimenez Fonseca
EGEnrique Gallardo
Enrique Gallardo
FAFernando Arranz Arija
Fernando Arranz Arija
JBJesús Manuel Blanco
Jesús Manuel Blanco
ACAna Callejo
Ana Callejo
ACAlberto Carmona-Bayonas
Alberto Carmona-Bayonas

21 April 2025 in Lung Cancer
Verified
Journal Article
Closed access
MGMatthias Guckenberger
Matthias Guckenberger
IOIsabelle Opitz
Isabelle Opitz
TDTereza Dellaporta
Tereza Dellaporta
ACAlessandra Curioni-Fontecedro
Alessandra Curioni-Fontecedro
Thomas FrauenfelderThomas Frauenfelder
Thomas Frauenfelder
RSRolf Stahel
Rolf Stahel

6 January 2022 in Acta Neurologica Belgica
Verified
Journal Article
Closed access
PDF file
SLSofía Lallana
Sofía Lallana
DSDaniel Sánchez-Tejerina
Daniel Sánchez-Tejerina
CACristina Auger
Cristina Auger
ACAna Callejo
Ana Callejo
JRJordi Rio
Jordi Rio
ACAlvaro Cobo-Calvo
Alvaro Cobo-Calvo

8 December 2021 in Research Square
Verified
Preprint
Open access
PDF file
ACAna Callejo
Ana Callejo
PIPatricia Iranzo
Patricia Iranzo
LOLaura Otal
Laura Otal
PGPaloma Gotor
Paloma Gotor
LBLola Berbiela
Lola Berbiela
RARaquel Andres
Raquel Andres
Introduction & objectives: Advances in early diagnosis and treatment are improving the long-term survival of patients with cancer. Cancer-related cognitive impairment (CRCI) is often reported as a long-term chemotherapy sequel. Improving the knowledge of CRCI may help to prevent, manage and identify risk factors. Our main goal is to assess the cognitive function evolution and determine the potential influence of chemotherapy in neurological decline. Material and methods We designed a prospective and longitudinal study of a colorectal and breast cancer patient cohort (n=62) and we assessed cognitive function evolution using a battery of 11 neuropsychological tests at three time points: baseline, post chemotherapy and 6 months after finishing chemotherapy. Sociodemographic features, quality of life, anxiety and depression status were recorded as well as their interplay with cognitive evolution. Results At baseline, 14.5% of the patients had cognitive dysfunction. Older age, low level of education, colorectal cancer and comorbidities were associated to initial cognitive damage. A total of 61.9% of patients presented a decline of scores in 4 or more tests from baseline to post chemotherapy assessment. This percentage decreased to 24.4% in the late follow up evaluation, showing an intra-patient recovery after chemotherapy. Verbal and visual memory is the domain most affected. Conclusion Our data suggest that cognitive function of cancer patients treated with chemotherapy may subtly but transiently decline during treatment, with most patients recovering their cognitive function over time. Further research is needed in this field as CRCI continues to impact on quality of life and mental well-being.